Riverbridge Partners LLC Purchases Shares of 14,257 Zoetis Inc. $ZTS

Riverbridge Partners LLC purchased a new stake in shares of Zoetis Inc. (NYSE:ZTS) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 14,257 shares of the company’s stock, valued at approximately $1,685,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Brighton Jones LLC boosted its stake in shares of Zoetis by 180.4% during the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after acquiring an additional 2,978 shares during the last quarter. Empowered Funds LLC increased its stake in shares of Zoetis by 6.2% in the 1st quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock worth $1,859,000 after purchasing an additional 657 shares in the last quarter. Intech Investment Management LLC raised its holdings in Zoetis by 17.2% in the 1st quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock worth $1,374,000 after purchasing an additional 1,224 shares during the period. Sivia Capital Partners LLC raised its holdings in Zoetis by 73.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock worth $522,000 after purchasing an additional 1,422 shares during the period. Finally, Glenview Trust co lifted its position in Zoetis by 11.8% during the second quarter. Glenview Trust co now owns 4,780 shares of the company’s stock valued at $745,000 after purchasing an additional 506 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

More Zoetis News

Here are the key news stories impacting Zoetis this week:

• Negative Sentiment: Multiple law firms announced or promoted class action lawsuits against Zoetis, with claims covering investors who bought shares between January 14, 2025 and May 6, 2026 and a lead-plaintiff deadline of July 27, 2026. The complaints allege investors were harmed by misleading disclosures about weakening veterinarian adoption and prescription trends. Article: Lost Money on Zoetis Inc. (ZTS)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky
• Negative Sentiment: A shareholder securities fraud lawsuit has already been filed, adding legal overhang and potentially increasing costs, management distraction, and headline risk for the stock. Article: SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Zoetis Inc. (ZTS)
• Neutral Sentiment: Zoetis was also mentioned in a broader healthcare momentum screen and brokerage commentary showing a “Hold” consensus, which suggests sentiment is cautious but not clearly improving. Article: 10 large and mega-cap U.S. healthcare stocks with the weakest momentum grades

Insider Buying and Selling

In related news, Director Michael B. Mccallister bought 3,000 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was bought at an average cost of $77.76 per share, with a total value of $233,280.00. Following the completion of the purchase, the director owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. The trade was a 13.94% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Paul Bisaro purchased 2,000 shares of Zoetis stock in a transaction on Wednesday, May 13th. The stock was bought at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the acquisition, the director owned 27,862 shares in the company, valued at $2,114,168.56. The trade was a 7.73% increase in their position. The SEC filing for this purchase provides additional information. Over the last quarter, insiders purchased 11,650 shares of company stock worth $886,384. 0.22% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

ZTS has been the topic of several recent research reports. Citigroup decreased their price objective on Zoetis from $145.00 to $112.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Wall Street Zen downgraded Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Argus restated a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. William Blair reaffirmed an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. Finally, UBS Group reduced their price objective on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a research note on Friday, May 8th. Six analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Zoetis currently has a consensus rating of “Hold” and an average price target of $133.92.

Zoetis Stock Performance

NYSE:ZTS opened at $78.14 on Thursday. The stock has a 50-day moving average price of $90.47 and a 200 day moving average price of $111.48. The stock has a market capitalization of $32.76 billion, a P/E ratio of 12.96, a P/E/G ratio of 1.20 and a beta of 0.75. Zoetis Inc. has a 12-month low of $72.38 and a 12-month high of $161.77. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The business had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. During the same quarter in the previous year, the company earned $1.48 earnings per share. The company’s revenue for the quarter was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities research analysts forecast that Zoetis Inc. will post 6.88 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be given a dividend of $0.53 per share. The ex-dividend date is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.7%. Zoetis’s dividend payout ratio is currently 35.16%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.